Comparison between fixed-dose, intracoronary bolus-only versus standard weight-adjusted dose, intravenous bolus and infusion administration of abciximab in patients undergoing primary percutaneous coronary intervention.
We studied the safety and effectiveness of fixed-dose, intracoronary bolus-only abciximab in 195 patients who underwent primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. The patients were divided into 2 groups: Group A (n=120, 61.5%) received fixed-dose, intracoronary bolus-only, abciximab 10 mg; and Group B (n=75, 38.5%) received standard intravenous bolus (0.25 mg/kg) and maintenance abciximab infusion of 0.125 μg/kg/min for 12 h. There was no statistically significant difference in the baseline and post-procedure TIMI flow between Groups A and B. Final TIMI 3 flow was achieved in 90.0% and 89.3% of the patients in Groups A and B, respectively (p=0.14). Final TIMI myocardial perfusion grade 2/3 was achieved in 92.5% and 96.0% of the patients in Groups A and B, respectively (p=0.45). The six-month clinical outcomes were similar between Groups A and B (8.3% versus 5.3%, p=0.62).
Lee
Chi-Hang
CH
National University Heart Centre, National University of Singapore, Singapore. Electronic address: mdclchr@nus.edu.sg.
Ngo
Hung M
HM
National University Heart Centre, National University of Singapore, Singapore.
Sewianto
Albert
A
National University Heart Centre, National University of Singapore, Singapore.
Nguyen
Tran Huy
TH
National University Heart Centre, National University of Singapore, Singapore.
Lee
Jieying
J
National University Heart Centre, National University of Singapore, Singapore.
Teo
Swee-Guan
SG
National University Heart Centre, National University of Singapore, Singapore.
Low
Adrian F
AF
National University Heart Centre, National University of Singapore, Singapore.
Tan
Huay-Cheem
HC
National University Heart Centre, National University of Singapore, Singapore.
D000077284:Abciximab; D000328:Adult; D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage*; D007261:Infusions, Intra-Arterial; D007262:Infusions, Intravenous; D007269:Injections, Intra-Arterial; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000503:physiopathology / Q000628:therapy
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D000077284:Abciximab